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MaThe prevention of cardiovascular disease (CVD) by using a polypill has gained increasing momentum as a strategy to
contain progression of the disease. Since its initial conception just over a decade ago, only a handful of trials have been
completed assessing the efﬁcacy and safety of this innovative concept. The results of these trials have supported the
viability of the polypill in CVD prevention and management, albeit with a few caveats, essentially related to the lack of
evidence on the effect of the polypill to effectively reduce cardiovascular events. The polypill has the potential to control
the global health epidemic of CVD by effectively reaching underdeveloped regions of the world, simplifying healthcare
delivery, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive prescription of
evidence-based cardioprotective drugs. Major trials underway will provide deﬁnitive evidence on the efﬁcacy of the
polypill in reducing cardiovascular events in a cost-effective manner. The results of these studies will determine whether
a polypill strategy can quell the burgeoning public health challenge of CVD and will potentially provide the evidence
to implement an effective, simple, and innovative solution to restrain the global CVD pandemic. (J Am Coll Cardiol
2014;64:613–21) © 2014 by the American College of Cardiology Foundation.N oncommunicable diseases have surpassedcommunicable diseases as the world’s majordisease burden, with cardiovascular disease
(CVD) remaining the leading global cause of death,
accounting for 17.3 million deaths per year, a ﬁgure
that is expected to grow to 23.6 million by 2030
(Fig. 1) (1,2). The overall aging population (projected
to almost double by 2060 in Europe and the United
States) (3) and improving survival of patients with
coronary heart disease (CHD) have created a large
pool of patients eligible for secondary prevention.
The administration of cardiovascular (CV) medica-
tions (e.g., statins, antihypertensive agents, anti-
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mated to be responsible for one-half of the overall 50%
observed reduction in mortality from coronary artery
disease over the past 20 years in some Western coun-
tries (4). This tremendous reduction in mortality
has been achieved despite patients not receiving the
most comprehensive, proven beneﬁt of contemporary
medical therapies.
Recent data highlight the massive treatment gap
and room for improvement in secondary prevention
on a global scale. The PURE (Prospective Urban Rural
Epidemiology) study showed that among participants
with a history of CHD or stroke, only 25% were taking
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ABBR EV I A T I ON S
AND ACRONYMS
BP = blood pressure
CHD = coronary heart disease
CV = cardiovascular
CVD = cardiovascular disease
FDC = ﬁxed-dose combination
LDL-C = low-density
lipoprotein cholesterol
LMIC = low- and-middle-
income countries
MI = myocardial infarction
RCT = randomized controlled
trial
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61420% were taking angiotensin-converting
enzyme inhibitors or angiotensin II receptor
blockers, and 15% were taking statins 5 years
after their event (5). In low- and middle-
income countries (LMIC) within the same
study, the use of these drugs was as low as 3%.
A recent meta-analysis of >375,000 patients
estimated adherence to CV medications at 2
years at 57% (6,7).
Rates of compliance with lifestyle modiﬁ-
cation and adherence to prescribed medica-
tions are alarming. More than 50% of patients,
on average, decide to abandon their pre-
scribed treatment, and the objectives to
improve habits (quit smoking, lose weight,or engage in physical activity) are met by an equally
low or lower percentage (8). Beyond the impact non-
adherence has on individual health, it carries a huge
economic cost because it is associated with a failure to
achieve therapeutic goals, higher rates of hospitaliza-
tion, and greater incidence of death. Reasons for
nonadherence to pharmacological therapy are com-
plex and have been studied in-depth (8–10). Most of
the reasons for suboptimal adherence can be grouped
into 4 categories: patient-, illness-, provider-, and
system-related factors (Central Illustration, Table 1).
Taken together, these considerations lead to inef-
fective CV prevention and a missed opportunity for
reducing CVD. One novel strategy seeking to address
adherence is the use of a ﬁxed-dose combination
(FDC) polypill. Incorporating the key medications
necessary to reduce CV risk into a single, once-daily
dose pill could increase use of an effective, inex-
pensive therapy, thereby lowering costs and
improving treatment adherence (11). The concept of
the polypill approach was introduced more than a
decade ago and has slowly progressed from a con-
ceptual debate to a therapeutic reality. Some of the
scientiﬁc community’s initial skepticism was due to
the sweeping proposal from Wald and Law (12), who
claimed that a polypill including 6 active compo-
nents administered to every individual older than
55 years of age would reduce the incidence of CVD by
>80%. This “vaccination approach” has never been
tested in a large population, and its efﬁcacy, poten-
tial adverse effects, and cost-effectiveness would
need to be assessed. Subsequently, the indication of
the polypill has been suggested in primary preven-
tion, speciﬁcally in individuals without previous
CVD, with no indication for statins or blood pressure
(BP)-lowering drugs, but who are at an overall high
risk of CV events. The efﬁcacy of this strategy
is currently being tested in 2 large randomized
trials. Finally, this third approach, the so-called“substitution approach,” would use the polypill in
patients already taking cardioprotective drugs for
secondary prevention. The rationale is straightfor-
ward: by improving adherence to treatment, avail-
ability, and efﬁciency, the polypill might serve as a
strategy to improve risk factor control and ultimately
decrease CV events on a global scale (13). Several
trials have tested the effect of this adherence
approach, with promising results. To date, however,
no large randomized controlled trial (RCT) has been
conducted to study the effect of the polypill strategy
on event recurrence.
CLINICAL DATA/ONGOING STUDIES
Evidence is available on the efﬁcacy, safety, tolera-
bility, and affordability of FDC polypills for the pri-
mary and secondary prevention of CVD.
PRIMARY PREVENTION. Several pilot studies have
demonstrated the feasibility of the primary preven-
tion strategy (14–17). The large, Phase II randomized
TIPS-1 (Indian Polycap Study–1) assessed the effects
of different pills containing either single agents or
combinations of drugs to measure their effect on
risk factors, such as BP and low-density lipoprotein
cholesterol (LDL-C) (18). The Phase II study also
evaluated the feasibility and tolerability of adminis-
tering a single pill to a relatively unselected group of
patients (characterized by having at least 1 CV risk
factor). Patients randomized to the polypill group
exhibited BP reductions similar to those assigned to 3
BP-lowering drugs and lower LDL-C reductions
compared with those receiving simvastatin alone. Of
interest, tolerability of the polypill was similar to
that of other treatments, regardless of the number of
active components in the 1 pill.
The PILL (Program to Improve Life and Longevity)
study reported similar ﬁndings in 378 subjects with no
indication for any component of the polypill and an
estimated 5-year Framingham risk score of >7.5%;
they were randomized to receive a polypill containing
aspirin 75 mg, lisinopril 10 mg, hydrochlorothiazide
12.5 mg, and simvastatin 20 mg or placebo for 12 weeks
(16). Over 12 weeks, polypill treatment reduced sys-
tolic BP by 9.9 mm Hg and LDL-C by 0.8 mmol/l,
translating to a 60% long-term reduction in risk for
both CHD and ischemic stroke. However, adverse ef-
fects (58% in the treated group vs. 42% in the placebo
group) and a drug discontinuation (23% in the polypill
arm vs. 18% in the placebo arm) were concerning.
Wald et al. (15) tested a polypill containing half-
standard doses of 3 antihypertensive agents (amlo-
dipine 2.5 mg, hydrochlorothiazide 12.5 mg, and
losartan 25 mg) and a standard 40-mg dose of
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FIGURE 1 Prevalence and Economic Burden of Cardiovascular Disease
(Top panel) Causes of death worldwide in 2011. Adapted with permission from Cannon
et al. (license no 3382581030803). (Bottom panel) total cost of illness, according to major
diagnosis, in the United States in 2009 (in USD billions). COPD ¼ chronic obstructive
pulmonary disease. Adapted from Sanz et al. (26).
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615simvastatin. In total, 84 individuals with no history of
CVD, who were candidates for primary prevention
based purely on their age ($50 years), completed the
trial. Participants took the polypill for 12 weeks and a
placebo for 12 weeks in a random sequence. On the
polypill, systolic and diastolic BPs and LDL-C levels
were reduced by 17.9 mm Hg (12%), 9.8 mm Hg (11%),
and 1.4 mmol/l (54 mg/dl; 39%), respectively. The
drug was well tolerated, and no participant experi-
enced a serious adverse event.
Malekzadeh et al. (17) evaluated the effects of a
polypill (a quadruple FDC therapy containing aspirin
81 mg, enalapril 2.5 mg, atorvastatin 20 mg, and
hydrochlorothiazide 12.5 mg) on levels of LDL-C,
systolic BP, and diastolic BP. The study included
50- to 79-year-old Iranian residents (N ¼ 475), without
CVD, hypertension, or hyperlipidemia and who were
not already taking antihypertensive drugs, statins, or
antiplatelet therapy. The patients were assigned
either to the polypill or placebo group for 12 months.
After controlling for baseline differences, the polypill
was associated with modest, yet statistically signiﬁ-
cant, reductions in BP (4.5/1.6 mm Hg), and LDL-C
(8.28 mg/dl) at 12 months. The ﬁndings suggest a
34% reduction in CHD risk and a 21% reduction in
stroke (28% for total CVD). These modest reductions
in BP and lipid levels were less than anticipated
(w50% of the expected efﬁcacy) for each of the drugs
in the polypill. There were imbalances in baseline
characteristics at randomization, and a high rate of
drug discontinuation (44% in the combination-pill
group and 33% in the placebo group at 12 weeks),
which could partially explain the relatively modest
risk factor reductions reported. Although the polypill
was well tolerated with an 11% discontinuation rate,
the consistency of the reported compliance measure
was uncertain. The study stressed the need for an
adequately powered trial of the polypill for the pri-
mary prevention of CVD.
SECONDARY PREVENTION. For secondary preven-
tion, TIPS-2 (Second Indian Polycap Study) reported
signiﬁcant reductions in BP and LDL-C in patients with
stable CVD or diabetes with the use of the combination
drugs used in TIPS-1. The polypill contained 3 BP-
lowering drugs (atenolol 50 mg, hydrochlorothiazide
12.5 mg, and ramipril 5 mg), simvastatin 20 mg, and
aspirin 100 mg. In total, 518 subjects eligible for sec-
ondary prevention were randomly allocated to receive
either a single polypill or 2 capsules of the polypill plus
potassium supplementation for 8 weeks. Compared
with the single dose, the double dose (or full dose)
reduced systolic and diastolic BPs and LDL-C levels by
an additional 2.8 mm Hg, 1.7 mm Hg, and 6.6 mg/dl,
respectively. Both doses were similarly well tolerated.The investigators anticipated that the full-dose
regimen would reduce the risk of CHD by 75%, and of
stroke by 65% (19), if this strategy was used in the
primary prevention setting, but they stressed that a
large RCT is required to prove this assertion.
The recently published UMPIRE (Use of a Multidrug
Pill In Reducing Cardiovascular Events) study was the
ﬁrst randomized trial designed to assess the long-term
effect of a FDC strategy in improving patients’ adher-
ence to medication in CV prevention (20). Adherence
to medication in the polypill group was 85%,
compared with 60% in the standard-care group (p <
0.001). The study included 2,004 patients (88% with
CVD) from 3 European countries and India. Patients
were randomly assigned to the FDC (21) strategy or to
usual care. Two different FDC strategies were used at
the physicians’ discretion: aspirin 75 mg, lisinopril 10
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CENTRAL ILLUSTRATION Patient Adherence and Reasons for Nonadherence to
Medications Prescribed as Secondary Prevention in Cardiovascular Disease
(Top) Patient adherence to medications prescribed as secondary prevention in cardio-
vascular disease (percent). (Bottom) Reasons for nonadherence to medications prescribed
as secondary prevention in cardiovascular disease. Effect of the polypill on adherence:
data from 3 randomized controlled trials (UMPIRE [Use of a Multidrug Pill In Reducing
Cardiovascular Events], IMPACT [Improving Adherence Using Combination Therapy], and
KANYINI-GAP [KANYINI-Guidelines Adherence with the Polypill]).
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616mg, simvastatin 40 mg, and either atenolol 50 mg or
hydrochlorothiazide 12.5 mg. At the end of the study
(median follow-up 15 months), adherence to medica-
tion in the polypill group was 85% compared with 60%
in the standard-care group (p <0.001). BP and LDL-C
levels were reduced with the FDC strategy to a
greater extent than with standard care, but the dif-
ferences were modest (2.6 mm Hg and 4.2 mg/dl,
respectively; p < 0.001 for each). No signiﬁcant dif-
ferences were reported in the incidence of serious
adverse effects between the groups.
The IMPACT (Improving Adherence Using Combi-
nation Therapy) trial evaluated 513 adults at high risk
of CVD (with established CVD or 5-year risk of $15%),
who were recommended for treatment with anti-
platelet, statin, and $2 BP-lowering drugs, and were
randomized to continued usual care or to FDCtreatment (with 2 possible approaches: aspirin 75 mg,
simvastatin 40 mg, and lisinopril 10 mg with either
atenolol 50 mg or hydrochlorothiazide 12.5 mg) and
included 12 months’ follow-up. The investigators
found that, in line with other studies, adherence to all
4 recommended drugs was greater among FDC than
usual care participants at 12 months (81% vs. 46%;
relative risk: 1.75 [95% conﬁdence interval: 1.52 to
2.03]; p < 0.001) (22).
The latest trial to explore the effect on adherence
of the polypill in secondary prevention has just been
published and included 623 patients with established
CVD or an estimated 5-year CVD risk $15% (21).
After a median of 18 months, patients randomized to
the polypill exhibited a signiﬁcantly higher adher-
ence than those receiving usual care (70% vs. 47%;
p < 0.001). The study found no signiﬁcant differ-
ences in BP or LDL-C levels between groups, possibly
due to the limited power of the study.
ONGOING STUDIES. Several large, ongoing studies
are testing the ability of different polypills to reduce
the presentation of new CV events in real-world prac-
tice. TIPS-3, HOPE-3 (Heart Outcomes Prevention
Evaluation–3), PolyIran (Prevention of Cardiovascular
Disease in Middle-aged and Elderly Iranians Using a
Single PolyPill), and FOCUS studies are currently un-
derway testing a combination pill against placebo.
TIPS-3 will evaluate a preparation of the Polycap
without aspirin (either the doses used in the ﬁrst TIPS
trial or enhanced doses based on results of the TIPS-K
[Indian Polycap Trial–K] trial) versus placebo over
5 years in 5,000 subjects without CVD and with an
estimated risk of major CVD of 1% per year in India
and China.
The ongoing HOPE-3 trial is evaluating the concept
of combined BP and cholesterol-lowering medications
in subjects without vascular disease and with average
BP and cholesterol levels (23). The trial is being con-
ducted in 22 countries in North America, South
America, Europe, Africa, Asia, and Australia and will
soon complete enrollment of 12,500 subjects at mod-
erate risk (men age 55 years and women aged 65 years
with 1 risk factor or women aged 60 years with 2 risk
factors). Patients are randomized to receive rosuvas-
tatin 10 mg/dl alone, an FDC of candesartan 16 mg/dl
and hydrochlorothiazide 12.5 mg/dl alone, both, or
neither (2  2 factorial design) for 5 years. The main
outcomes will include major CVD events and changes
in cognitive and renal function.
The PolyIran study is seeking to determine the
effects of a polypill (an FDC of 2 antihypertensive
medications, atorvastatin, and aspirin) on primary
and secondary prevention of CVD in Iranian adults
older than 50 years (24). This ambitious trial will
TABLE 1 Reasons for Medication Nonadherence
Patient Related Illness Related Provider Related System Related
Psychological problems, particularly
depression
Asymptomatic disease Inadequate follow-up/discharge
planning
Availability/accessibility
of services
Cognitive impairment Medication adverse effects Warmth and empathy Cost of treatment
Lack of conﬁdence in beneﬁt
of treatment
Complexity of treatment Poor communication Support for patient education
Insight into illness Acute versus chronic Continuity of care Data/information management
Trust in provider Lack of immediate beneﬁt Poor provider–patient relationship Community support
Satisfaction with medical regimen Long duration Training provided
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617divide the cohort into 3 arms: 3,500 randomly
selected participants will receive the polypill once
daily and minimal care (which consists of direct ed-
ucation and a pamphlet on CV risk reduction, bian-
nual follow-ups, and BP measurements); 3,500
randomly selected participants will receive only the
aforementioned minimal care; and 24,000 partici-
pants will receive usual care (standard primary health
care provided by the local physicians and community
health workers for the whole participants of the
Golestan Cohort Study, consistent with the current
Iranian Health Care System guidelines). The ﬁrst and
second arms will be compared via a 2-arm, open-
label, cluster RCT. The comparisons between arm 3
and the other 2 arms will be performed by means of a
cohort, multiple RCT design. Endpoints will include
major CV events (death and hospitalization).
HOPE-4 (Heart Outcomes Prevention Evaluation–4)
is a community cluster RCT that will evaluate an
evidence-based program for CVD risk assessment,
treatment, and control involving simpliﬁed screening
and treatment algorithms implemented by nonphysi-
cian health workers coupled with lifestyle counseling
and combination-pill therapy (25). The initial risk
factor phase of the study will assess BP and choles-
terol changes in Colombia and Malaysia (50 commu-
nities), with plans to expand to 190 communities in
8 countries to evaluate CVD events over 6 years.
The FOCUS project will evaluate the impact of the
polypill on patient adherence to treatment. FOCUS
consists of 2 separate, prospective phases. Phase 1 is a
comprehensive analysis in 5 countries of factors that
impede appropriate use of cardioprotective medica-
tions. Phase 2 is an RCT, testing the effects of a
combination polypill on adherence, BP, and lipids at 9
months in a post–myocardial infarction (MI) cohort
(26). The results will be presented this year and will
help answer some elemental questions regarding the
real impact of the polypill on adherence in a large
cohort of post-MI patients, as well as provide a better
understanding of the contemporary barriers to car-
dioprotective medication adherence in secondaryprevention. The designs of the major trials using the
polypill are included in Table 2.
ECONOMIC BURDEN OF DISEASE AND COST-
EFFECTIVENESS STUDIES. The economic impact of
CVD in 2009 was estimated at V196 billion in Europe
(27) and $313 billion in the United States, representing
around 17% of overall national health expenditures in
the United States, with direct healthcare costs making
up approximately 61% (28). The U.S. economic
burden of diseases according to major diagnosis is
depicted in Fig. 1. In a U.S. retrospective analysis of
healthcare insurance claims of adults hospitalized for
acute coronary syndrome between 2003 and 2006,
the cost of the index acute coronary syndrome hos-
pitalization was $27,101, which was 49% of the total
annual healthcare costs. Prescriptions accounted for a
small proportion of all costs; the mean cost of CV
prescriptions was $2,337 (29).
Medication nonadherence results in a huge medi-
cal and economic burden, carrying responsibility for
194,500 deaths per year in Europe, leading to an
estimated cost of V125 billion annually in Europe and
$300 billion annually in the United States (30). The
results of a systematic review studying the impact of
medication adherence on coronary artery disease
costs and outcomes have recently been published.
The authors concluded that high adherence to CV
medication signiﬁcantly improves healthcare out-
comes and reduces annual costs for secondary pre-
vention of coronary artery disease (between $294 and
$868 per patient, equating to 10.1% to 17.8% cost re-
ductions between high- and low-adherence groups)
(31). The results of this systematic review underline
the potential for a strategy that increases adherence
to improve outcomes and cut costs.
Different pharmacoeconomic models all have
generally concluded that secondary prevention is
highly cost-effective. In this regard, Ito et al. (32)
evaluated the comparative cost-effectiveness of
interventions to improve adherence to evidence-
based medications among post-MI patients. Sensi-
tivity analyses showed that, among the different
TABLE 2 Fixed-Dose Combinations in CV Prevention Studies
Population Polypill Composition Outcomes Status
Primary prevention
TIPS (Indian Polycap Study),
N ¼ 2,053, Yusuf S,
Pais P (18)
Men and women aged 40–80 yrs
without CVD and with at least
1 CV risk factor in India
Aspirin 100 mg, simvastatin
20 mg, ramipril 5 mg,
hydrochlorothiazide 12.5 mg,
atenolol 50 mg
Feasibility; effect on risk
factor levels; safety
and tolerability
Completed
PolyIran (Phase II Study of Heart
Polypill Safety and Efﬁcacy
in Primary Prevention of
CV Disease), N ¼ 475;
Marshall T, Malekzadeh R,
Malekzadeh F (17)
Men and women aged 50–80 yrs
without indications or
contraindications for aspirin,
BP-lowering drugs, and
statins in Iran
Aspirin 81 mg, hydrochlorothiazide
12.5 mg, enalapril 2.5 mg,
atorvastatin 20 mg
Effect on risk factor levels;
safety and tolerability
Completed
Combination Therapy Trial,
N ¼ 200; Furberg C,
Mendis S, Soliman EZ (14)
Age >40 yrs without CVD and
with estimated 10-yrs total
CVD risk score >20% in
Sri Lanka
Aspirin 75 mg, simvastatin
10 mg, lisinopril 10 mg,
hydrochlorothiazide 10 mg
(“red heart pill 2b”)
Effect on estimated 10-y
total CVD risk score
Completed
IMPACT (Improving Adherence
Using Combination
Therapy), N ¼ 497;
Rodgers A, Selak A (16)
Established CVD or 5-yr
risk $15%
Aspirin 75 mg, simvastatin 40 mg,
and lisinopril 10 mg with
either atenolol 50 mg or
hydrochlorothiazide 12.5 mg
Effect on adherence to
recommended drugs and
mean change in BP and
LDL-C at 12 months
Completed
TIPS-3 (Indian Polycap Trial–3),
N ¼ 5,000; Yusuf S,
Pais P, Xavier D, Liu L (18)
Primary prevention with estimated
yearly CVD event rate of >1%
using the INTERHEART risk
score in China and India
Polycap; dose to be chosen after
completion of the TIPS-K
(Indian Polycap Trial–K) trials
Major CVD events;
neurocognitive function
Estimated study
completion date:
January 2019
HOPE-3 (Heart Outcomes
Prevention Evaluation–3)
(23)
N ¼ 12,500; Yusuf S,
Lonn E
Primary prevention in men aged
>55 yrs and women age
>65 yrs with at least 1 CV risk
factor and women age >60 yrs
with at least 2 risk factors
and with average BP and
cholesterol levels in
22 countries
Rosuvastatin 10 mg, candesartan
16 mg/hydrochlorothiazide
12.5 mg (2  2 factorial design)
Major CVD events;
neurocognitive function;
renal function
Estimated study
completion date:
March 2016
Secondary prevention
FOCUS Trial in Secondary
Prevention; Phase 1,
n ¼ 2,000, Phase 2,
n ¼ 800; Fuster V (26)
Survivors of myocardial infarction
in Spain and Latin American
countries
Aspirin 100 mg, simvastatin
40 mg, ramipril 2.5, 5, or
10 mg (Trinomia)
Adherence; feasibility;
effect on risk factor levels;
safety and tolerability
Estimated study
completion date:
June 2014
UMPIRE (Use of a Multidrug Pill
In Reducing CV Events) (20)
N ¼ 2,000; Thom SA,
Rodgers A
Established CVD or high-risk
primary prevention (5-yr CVD
risk of >15%) in India, the
Netherlands, United Kingdom
Aspirin 75 mg, atenolol 50 mg,
simvastatin 40 mg, lisinopril
10 mg (“red heart pill 1”) or
aspirin 75 mg, hydrochlorothiazide
12.5 mg, simvastatin 40 mg,
lisinopril 10 mg (“red heart
pill 2”)
Adherence; effect on risk
factor levels; safety and
tolerability; CVD events
(secondary outcome)
Completed
BP ¼ blood pressure; CV ¼ cardiovascular; CVD ¼ cardiovascular disease; LDL-C ¼ low-density lipoprotein cholesterol.
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618interventions, the polypill when combined with
mailed education could potentially be a cost-saving
strategy if its monthly costs decreased to less than
$100 per patient.
CVD remains the most common cause of death in
all developing countries (excluding sub-Saharan Af-
rica, where it is the second) (33). Despite the proven
beneﬁts of cardioprotective drugs, these effective,
inexpensive treatments are largely underused in
developing countries, even in secondary prevention.
In addition, industry standards producing generic
drugs are not always guaranteed. The proposition of
the FDC polypill is that by using a polypill containing
components with proven efﬁcacy, its availability and
adherence would increase, rendering the polypill amuch-needed efﬁcient strategy to prevent CVD in
LMIC.
The cost-effectiveness of a polypill regimen for
patients at high risk for CVD speciﬁcally in the
setting of LMIC has also been tested. Gaziano et al.
(34) performed a pharmacoeconomic study assessing
2 combination regimens, 1 for primary prevention
(which included aspirin, a calcium channel blocker,
an angiotensin-converting enzyme inhibitor, and a
statin) and another for secondary prevention (which
included the same combination of drugs in group 1
but substituted a beta-blocker for the calcium-
channel blocker). The incremental cost-effectiveness
ratio for the secondary regimen was between
$306 and $388 per quality-adjusted life-year,
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619indicating a cost-effective intervention for patients
with CVD in all developing regions, even in low-
income countries.
THE CNIC-FS-FERRER POLYPILL PROJECT:
FROM CONCEPT TO REALITY
The Centro Nacional de Investigaciones Cardio-
vasculares (National Center for CV Investigations
[CNIC]), together with Ferrer Internacional, has
developed a once-daily polypill for secondary CV
prevention, consisting of acetylsalicylic acid 100 mg,
simvastatin 20 mg, and ramipril 2.5 mg/5 mg/10 mg
(26). Each component of the combination has a well-
proven efﬁcacy to prevent recurrence of CV events,
and the dosages selected for inclusion are based on
achieving the best balance between efﬁcacy and
safety. The CNIC-FS-Ferrer polypill is now ap-
proved and being commercialized in Guatemala,
Mexico, Nicaragua, Dominican Republic, Argentina,
Honduras, and El Salvador. A second formulation
(consisting of acetylsalicylic acid 100 mg, atorvastatin
20 mg, and ramipril 2.5 mg/5 mg/10 mg) has been
approved by various agencies in Europe. This polypill
has been developed within a very clear conceptual
frame to improve adherence, accessibility, effective-
ness, and therefore cost-effectiveness, and has been
extensively tested in preclinical and clinical studies,
including the aforementioned FOCUS study.
A GLOBAL SCENARIO FOR A
POLYPILL STRATEGY
The public health beneﬁts of the polypill could
potentially carry a worldwide impact, providing a
viable solution to a growing global health concern.
Currently, there are 2 global scenarios in which the
polypill could be used, for different reasons. First, in
a setting of high-income countries, we are experi-
encing the “CVD paradox” (35), in which worldwide,
all-cause mortality declined and life expectancy
increased by 9 years between 1979 and 2004 (36).
Age-related CVD mortality has also been declining
over the past 25 to 30 years, mainly due to risk factor
reductions and treatment of established disease
(each accounting for approximately 40% to 60% of
the decline in CVD mortality). Despite ground-
breaking advances in technology and treatment and
reductions in age-related CVD deaths, unless the
incidence of CVD decreases in accordance with the
decline in mortality over the next 20 to 30 years, we
will experience a rise in the prevalence of CVD. Sec-
ond, 1 in 3 Americans (36.9%) currently suffer from
some form of heart disease, including hypertension,CHD, heart failure, stroke, and other conditions. It is
projected that by 2030, approximately 116 million
people in the United States (40.5%) will have some
form of CVD (37). Healthcare costs are increasing
worldwide, mostly because of the use of important
but expensive new technologies and treatments, but
also as a result of people surviving for longer and
therefore requiring more health care (including hos-
pitalization) (38) over their lifetime. The cost asso-
ciated with treating CVD has risen dramatically, and
it is predicted that between 2010 and 2030, the cost
of medical care for heart disease (in 2008 dollar
values) will triple, rising from $273 billion to $818
billion (37). Moreover, heart disease also will cost the
nation billions more in lost productivity, increasing
from an estimated $172 billion in 2010 to $276 billion
in 2030.
It has become clear that to avoid a decline in the
quality of life and avoid the increasing cost of tech-
nologies and therapies to treat CVD, we must focus on
efﬁcient strategies that promote CV health and pre-
vent CVD. Nearly 30% of all heart attacks that happen
in the United States every year are recurrent events
(38). CVD prevalence worldwide is expected to
further increase as a result of the epidemic of obesity
and its consequences, including diabetes, hyperten-
sion, and dyslipidemia. Hence, in the setting of
developed, wealthy nations with high accessibility to
care, the FDC polypill is expected, with the upcoming
data from ongoing clinical trials, to signiﬁcantly in-
crease the effectiveness of CV medications largely by
improving adherence levels and, therefore, reducing
indirect and direct costs.
Nevertheless, CVD does not affect the world
homogenously: indeed, 80% of CVD deaths occur in
LMIC (39). Healthcare systems in these countries
often do not allow for robust health care, making it
more challenging to combat CVD. Often, there is
a severe shortage of physicians, healthcare practi-
tioners, ﬁnancial means, clinics, medicine, and
follow-up care (40). At present, there is no consensus
regarding for which patient population the polypill
should be prescribed. Although emerging data
will help reﬁne indications for the polypill, it is
possible that these indications may be broader in
LMIC settings. For such a strategy to be effectively
implemented, it is critical that the consensus
should consist of a few selected criteria, thereby
substantially simplifying treatment algorithms to
reach the majority of patients at risk for CVD. The
polypill is administered as a simple, 1-pill-per-day
regimen, with no substantial tolerability issues or
monitoring requirements. In addition, it can be dis-
tributed as a cost-effective alternative to its multi-pill
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620counterparts. In this scenario, the healthcare systems
of LMIC, which do not have the means to ensure
adequate patient services, can adopt the polypill
strategy because patients should be able to manage it
autonomously.
In settings with fewer resources, a polypill strategy
is potentially critical considering that a 1-month sup-
ply of standard generic secondary prevention medi-
cations can cost a government worker in a low-income
country approximately 1.6 to 18.4 days of work wages
(40). From a business model point of view, one of the
major appeals of an FDC polypill is the use of low-cost
mature drugs in an efﬁcient manner. This process
increases availability to treatment and renders the
polypill as part of an integral strategy to reduce CVD
morbidity and mortality in LMIC, which typically
cannot afford the huge losses in human and ﬁnancial
resources that result from this disease.
CHALLENGES AND FUTURE DIRECTIONS
There are impressive, potential beneﬁts that come
with the use of a polypill strategy in CV prevention.
Unfortunately, the use of a polypill for CV prevention
is relatively novel, and although data from clinical
trials are accumulating, the clinical question that re-
mains to dissipate skepticism is whether the polypill,
beyond improving adherence and risk factor control as
surrogate markers, can signiﬁcantly reduce CV events.
The polypill has its own share of controversy due to the
initial, vaccination strategy proposed byWald and Law
(12), which has never been proven and of which the
safety and feasibility remain largely unknown. Skep-
tics also are concerned that patients will regard the
polypill as an excuse to potentially replace efforts to
promote healthy lifestyles. The reasoning is that if
patients assume an overvalued outlook on the polypill
that will protect them from exposure to all CV risk
factors, they may feel that they have the freedom to
adopt inappropriate lifestyles without consequences.
In this regard, the UMPIRE trial has provided direct
randomized data demonstrating that people who
knew they were taking a polypill showed no adverse
effect on lifestyle measures, such as weight, exercise,
or smoking (20).
An FDC polypill should be part of an integral pro-
gram of secondary CVD prevention including lifestyle
modiﬁcation, which should remain a primary compo-
nent in the armamentarium of CVD prevention. How-
ever, in clinical practice, successful and sustained
lifestyle modiﬁcation is achieved in only a small pro-
portion of patients. Furthermore, nearly one-half of
patients with established coronary disease abandon
effective treatment after 6 months (8). Thus, from apublic health point of view, we may not have the time
or luxury of waiting to assess the effects of lifestyle
counseling before resorting to evidence-based drug
therapy in high-risk individuals, thereby delaying
cost-effective care that has been shown to signiﬁcantly
enhance medication adherence and improve risk fac-
tor control. Instead, it is appropriate to initiate life-
style modiﬁcation simultaneously with drug therapy
because the beneﬁts are complementary and additive
for CVD prevention.
CONCLUSIONS
Despite major advances in all ﬁelds of CV medicine,
CVD remains a prevalent global health issue, with a
projected increasing incidence over the next 2 de-
cades. The worldwide increase in life expectancy
and the consequential aging of the population will
result in more subjects developing CVD and requiring
treatment for their condition. Coupled with the
improvement in life expectancy in patients with
established CVD, the associated high healthcare costs
may make provision of modern technology and
treatments to such a vast number of people unfeasi-
ble. The use of a polypill strategy offers a novel
and effective solution for those who have poor
access to care and budget constraints, while simpli-
fying healthcare delivery and prescription, improving
cost-effectiveness, and supporting completeness of
evidence-based prescribing. In nations with limited
resources, the polypill may ultimately provide better
protection than inefﬁcient, sophisticated care.
The polypill has immense potential, few adverse
effects, and robust supportive evidence. Strong,
comparable alternatives are sparse. As such, it has
received the attention of the Wellcome Trust and the
World Health Organization, and is endorsed by the
World Heart Federation and other authorities con-
cerned about the inordinate burden of CHD.
Available clinical data support the viability of the
polypill in CVD prevention and management but with
a few reservations. Studies are being conducted
around the world as investigators unite to determine
whether it is a viable solution to an epidemic facing
every country, race, and community. Gradually, the
role of the polypill in CV prevention is being deﬁned.
Further research of the polypill is needed, with the
collective results having the potential power to
change the face of health care across the world.
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